For the Inventor, By the Inventor

Enter assignee name

Carmiel, Israel

Protalix Ltd.

USPTO Granted Patents = 25

CIPO Patents = 16

EPO Patents = 20

Trademarks = 1

Forward Citations = 100

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 15 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (8 out of 8 patents)

5. Gideon Baum (8 out of 12 patents)

6. Uri Hanania (7 out of 7 patents)

7. Sharon Hashmueli (7 out of 7 patents)

8. Daniel Bartfeld (7 out of 7 patents)

9. Ayala Lewkowicz (6 out of 6 patents)

10. Talia Shekhter (5 out of 5 patents)

11. Yaniv Azulay (5 out of 5 patents)

12. Liat Fux (4 out of 4 patents)

13. Tehila Ben-Moshe (4 out of 9 patents)

14. Svetlana Gingis-Velitski (3 out of 3 patents)

15. Tami Ariel (3 out of 3 patents)

25 patents: Sort by Forward Citations

1. 12385054 - Removal of constructs from transformed cells (2025-08-12),

2. 12385026 - Stabilized alpha-galactosidase and uses thereof (2025-08-12),

3. 12194079 - Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase (2025-01-14),

4. 11814657 - Modified DNase and uses thereof (2023-11-14),

5. 11225648 - Modified DNase and uses thereof (2022-01-18),

6. 10870842 - Stabilized alpha-galactosidase and uses thereof (2020-12-22),

7. 10730925 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2020-08-04),

8. 10364413 - Large scale disposable bioreactor (2019-07-30),

9. 10280414 - Stabilized α-galactosidase and uses thereof (2019-05-07),

10. 10087232 - Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy (2018-10-02),

11. 10000551 - Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same (2018-06-19),

12. 9732333 - Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells (2017-08-15),

13. 9708595 - Stabilized alpha-galactosidase and uses thereof (2017-07-18),

14. 9603907 - Dry powder formulations of dNase I (2017-03-28),

15. 9603906 - Inhalable liquid formulations of DNase I (2017-03-28),

Protalix Ltd. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company utilizes its proprietary ProCellEx® platform to produce unique and advanced biologic drugs. Protalix is committed to improving and transforming the lives of patients suffering from various diseases, including genetic disorders and immune-related conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

25 Patents

#1 in Carmiel

#222 in Israel

#24,897 in the World

Carmiel, Israel

Protalix Ltd.

Forward Citations = 100

51 inventors:

Yoseph Shaaltiel (23 out of 23 patents)

Avidor Shulman (11 out of 15 patents)

Tali Kizhner (11 out of 11 patents)

4. Ilya Ruderfer (8 out of 8 patents)

5. Gideon Baum (8 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…